TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: ratings of autistic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amelioration of hyperactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Downregulation of genes related to energy metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Luminal distension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perception of youthfulness after therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of TNF-alpha-secreting monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of T cells secreting IL-2 and interferon-gamma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Level of serum soluble IL-2R (sIL-2R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Conversion to psychosis rate
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in prodromal positive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: airway responsiveness to histamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Patient comfort with telephone therapy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Perceived benefits of telephone therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Awareness of the program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Identification of the healthy eating message
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CSP (Cortical Silent Period)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ICF (Intracortical Facilitation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in Body Mass Index (BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in physical activity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Episodes of toxoplasmic encephalitis
Endpoint domain: Adverse events/effects
Primary endpoint: CIBIC+ score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Indwelling time of thoracic drainage tube
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Accuracy of /r/ productions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left anterior cingulate thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: White matter and subcortical gray matter hyperintensities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain reduction during infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hyperalgesic response after withdrawal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in cases on the BDI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean level of IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: WHO-BREF QOL score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Oxygenated hemoglobin change (ΔHbO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Glycaemic control (mean HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nocturnal confirmed hypoglycaemia
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients achieving target A1C <7.0%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rates of hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity of CDFI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Specificity of CDFI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Positive predictive value (PVpos) of CDFI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Negative predictive value (PVneg) of CDFI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: reperfusion-associated low blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: post-reperfusion blood flow velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean rate of corneal epithelial wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bodily retraction of upper anterior teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suppression of OUCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of fasting tHcy levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Completion rate for follow-up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: days of community buprenorphine treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of developing liver enzyme elevation during pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Days of opioid use reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: obesity odds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: high depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Daily hepatic volume growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total bilirubin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lack of motor block (MB) as evaluated by the modified Bromage scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean fasting plasma glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cormack and Lehane grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of glottic opening visible (POGO score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cooling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of ACT-709478
Endpoint domain: Adverse events/effects
Primary endpoint: increased vegetable consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Noradrenaline administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to the first occurrence of ischemic stroke, intracerebral hemorrhage, or death
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in adjusted HDRS17 total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-treatment plasma MDA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in adverse responses
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in good clinical pharmacy practice
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in drug toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Mental health impairment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adverse Events (AEs) of grade 3 or 4
Endpoint domain: Adverse events/effects
Primary endpoint: Oral and denture hygiene improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pregnancy or impregnating someone by age 18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Completion rate of PICC indication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leiomyoma volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concern scores of the uterine leiomyoma symptom quality-of-life subscale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean trough reduction in SeDBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number and percentage of responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of study drug-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: number of fogging events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Total volumetric bone mineral density (vBMD) at the radius and tibia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cortical thickness at the tibia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Finite element analysis‐estimated strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in alcohol-related RSB outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Episodes of common cold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Episodes of fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Episodes of coughing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Postoperative FSFI score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: gingival scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with a modified Rankin score of 2 or less at 90 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with symptomatic intracerebral hemorrhage within 30 hours after initiation of t‐PA
Endpoint domain: Adverse events/effects
Primary endpoint: new untreated carious lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rhinoconjunctivitis symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: skin sensitivities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase in estrin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Use of modern contraception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in center-of-mass sway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in fear of falling (FES-I)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Increase in number of walking bouts
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: peak heart rate reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: peak blood pressure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: N-terminal pro-brain natriuretic peptide concentration reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in plasma thiobarbituric reactive substances
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Inhibition of myometrial contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating neutrophil count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lymphocyte proportion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 90-day mortality rates
Endpoint domain: Mortality/survival
Primary endpoint: average roughness of ceramic samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lowest systolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sleep medication use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postprandial triglyceride dAUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: triglyceride AUC in chylomicron fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: FFA AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: drinking frequency and quantity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF-36 emotional limitation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of VGE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: contrast-to-noise ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: delineation of pancreatic parenchyma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: delineation of pancreatic tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in migraine days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in days with acute medication use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Staphylococcus aureus colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Improvement in barrier function (transepidermal water loss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Aβ1‐40 serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aβ1‐42 serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days of moderate and vigorous physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days engaged in muscular strength/endurance training
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days engaged in activities to manage weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adoption of healthy lifestyle habits
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in IPSS items
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life (QOL) index improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: time-averaged maximum velocity (TAMX) in the superior mesenteric artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: time-averaged maximum velocity (TAMX) in the portal vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Mean changes in the Roland Morris Disability Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Prevalence of psoriasis
Endpoint domain: Mortality/survival
Primary endpoint: Risk of ACS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiac matrix metalloproteinase-2 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fighting spirit
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hospital re-admission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: MPO levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: LF levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: CD66b expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Desaturation rates (SpO2 < 94% and < 90%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Feelings of gratitude
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Surface Microhardness Change (%SMC) on enamel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluoride concentration in test plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TFA (Time to First Analgesic)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participant-days achieving step goals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean daily steps compared with baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risky Driving Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agatston score agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of categorical treatment response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical function domain scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: hospitalization for cardiovascular reasons
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Straight Leg Raise Test (SLET)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emotional aspects improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical Global Impression‐sexual function score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge of reproductive issues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: abnormal changes in safety parameters and vital signs
Endpoint domain: Adverse events/effects
Primary endpoint: clinically relevant adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Relapse into depression
Endpoint domain: Adverse events/effects
Primary endpoint: Relapse into psychosis
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in externalising symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean concentrations of levofloxacin and ofloxacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Improvement in regional myocardial perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in ischaemic threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma levels of cortisol and catecholamines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: IL-6 and CRP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: LDL particle counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HDL particle size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: plasma TG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients achieving target goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: incidence of stents with ≥ 5.9% uncovered struts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: percentage of malapposed struts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: QIDS-CL scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Euphoric effects of OROS-MPH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of drinks per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Binge-drinking episodes per month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frontal and centroparietal alpha absolute power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sustained biochemical and virological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived availability of built environment structures
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Perceived condition of built environment structures
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: neural markers of fear reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: PANSS scores for positive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PANSS scores for negative symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TESS score
Endpoint domain: Adverse events/effects
Primary endpoint: Posttreatment satisfaction with CD treatment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Awakening time of patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total 1-year medical care costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use